Kriya Therapeutics completed a $313 million financing round to advance its portfolio of gene therapies targeting ophthalmic, metabolic, and neurologic chronic diseases. The investment follows previous fundraising rounds exceeding $500 million and supports continued development of AAV vector-based therapies, despite safety concerns associated with viral vectors reported in recent gene therapy trials.